Bioxytran (BIXT) Debt Ratio (2010 - 2026)

Bioxytran (BIXT) posted Debt Ratio of 0.58 for Q1 2026, down 3.8% sequentially from 0.6 in Q4 2025, and up 63.82% YoY from 0.35 in Q1 2025.

Bioxytran (BIXT) Debt Ratio (2010 - 2026) Analysis & Trends

Bioxytran has reported Debt Ratio for 16 years, with the latest figure at 0.58 in Q1 2026.

Quarterly Debt Ratio rose 63.82% year-over-year to 0.58 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.58 (up 63.82% YoY) and the FY2025 annual result came in at 0.6, down 65.43% from the prior year.
Debt Ratio retreated to 0.58 in Q1 2026 per BIXT's latest filing, from 0.6 in the prior quarter.
Over five years, Debt Ratio peaked at 15.42 in Q4 2023 and troughed at 0.24 in Q3 2024.
A 5-year average of 5.28 and a median of 4.15 in 2022 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2024 and 2025: Debt Ratio plunged 97.65% in 2024, then surged 1349.49% in 2025.
Over 5 years, Debt Ratio stood at 6.2 in 2022, then soared by 148.67% to 15.42 in 2023, then plunged by 88.72% to 1.74 in 2024, then sank by 65.43% to 0.6 in 2025, then declined by 3.8% to 0.58 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.58, 0.6, and 3.46 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.05
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.03
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	Bioxytran	2.52 Mn	2.27 Mn	-	1.07

Download Data